Citi lowered the firm’s price target on Xenon Pharmaceuticals to $60 from $62 and keeps a Buy rating on the shares post the Q1 report. The company noted progress on execution of Phase 3 programs of azetukalner with no surprises, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XENE:
- Xenon Pharmaceuticals Advances Drug Trials
- Xenon Pharmaceuticals: Engaging Investors with Regular Updates
- Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Xenon Pharmaceuticals to Highlight Advances at Health Care Conference
- Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2024
Questions or Comments about the article? Write to editor@tipranks.com